RxDoctor Payments Data

Sunil Patel, DO

Nephrology · Apple Valley, CANPI 1134274012

Payments from drug & device makers

$508,672in general payments, 2019–2025

Across 1,203 payments — averaging $422.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$284K
  • Akebia Therapeutics Inc$90K
  • GSK$47K
  • Bayer$35K
  • AstraZeneca$31K
  • Calliditas Therapeutics US Inc.$7K
  • plus $15K from 39 others

What the payments were for

  • Consulting fees$36,0807%
  • Speaking & faculty fees$334,84166%
  • Travel & lodging$115,04723%
  • Food & beverage$22,3854%
  • Education$1690%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$508,672 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$469,331
Medicare patients
241
Services billed
4,877

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KrystexxaPegloticase99$5,413,334
KerendiaFinerenone244$204,270
RayaldeeCalcifediol138$203,197
FarxigaDapagliflozin Propanediol292$194,546
XphozahTenapanor Hcl61$177,757
LupkynisVoclosporin12$177,210
AuryxiaFerric Citrate108$169,868
VelphoroSucroferric Oxyhydroxide33$120,800
TrulicityDulaglutide104$117,376
LokelmaSodium Zirconium Cyclosilicate135$106,884
OzempicSemaglutide105$104,252
JardianceEmpagliflozin136$97,665
MounjaroTirzepatide74$88,644
DapagliflozinDapagliflozin Propanediol143$72,732
EliquisApixaban105$67,189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa$284,433$5,413,33499 claims
AstraZenecaFarxiga, Lokelma$30,861$301,429427 claims
Lilly USA, LLCTrulicity, Mounjaro$281$206,020178 claims
BayerKerendia$35,272$204,270244 claims
OPKO Pharmaceuticals, LLCRayaldee$659$203,197138 claims
Aurinia Pharma U.S., Inc.Lupkynis$258$177,21012 claims
Akebia Therapeutics IncAuryxia$89,576$169,868108 claims
Fresenius USA Marketing, Inc.Velphoro$44$120,80033 claims
Novo NordiskOzempic, Rybelsus$621$114,919117 claims
Boehringer IngelheimJardiance$484$97,665136 claims
MerckJanuvia, Verquvo$752$87,579122 claims
PfizerEliquis$75$67,189105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.

Other nephrology in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →